Literature DB >> 18033226

Renal disease in patients with cancer.

Kevin W Finkel1, John R Foringer.   

Abstract

Kidney disease is very common in patients with cancer. Nephrologists are vital members of the multidisciplinary care team for these patients. Given the high prevalence of comorbidities in patients treated for active malignancy, it is not surprising that these individuals frequently develop renal diseases that are common among other hospitalized patients, such as those arising from sepsis, hypotension or use of nephrotoxic agents (e.g. radiocontrast or antimicrobial agents). The role of the nephrologist in these cases differs little with respect to the presence or absence of cancer. On the other hand, there are several renal syndromes that are unique to patients with cancer, being caused either by the cancer itself or by its treatment. These syndromes are reviewed here. In addition, patients who are receiving chemotherapy often require dialysis for either acute or chronic kidney disease. Unfortunately, there is very little information on the clearance characteristics of most chemotherapeutic agents. In cancer patients with renal disease, both the timing of administration and the dose-adjustment of chemotherapy must rely on clinical experience and close clinical observation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18033226     DOI: 10.1038/ncpneph0622

Source DB:  PubMed          Journal:  Nat Clin Pract Nephrol        ISSN: 1745-8323


  5 in total

Review 1.  Chronic kidney disease and cancer: a troubling connection.

Authors:  Benedicte Stengel
Journal:  J Nephrol       Date:  2010 May-Jun       Impact factor: 3.902

2.  Kidney Failure with Urinary Tract Cancers.

Authors:  Ankur Shah; Susie L Hu
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-06       Impact factor: 8.237

3.  Acute kidney injury in cancer patients and impedance cardiography-assisted renal replacement therapy: Experience from the onconephrology unit of a Chinese tertiary hospital.

Authors:  Tao Wang; Yan Zhang; Qingxia Li; Shumin Jia; Changjin Shi; Kai Niu; Bing Liu
Journal:  Exp Ther Med       Date:  2017-10-02       Impact factor: 2.447

4.  A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.

Authors:  Analía Azaro; Jordi Rodón; Jean-Pascal Machiels; Sylvie Rottey; Silvia Damian; Richard Baird; Javier Garcia-Corbacho; Ron H J Mathijssen; Pierre-François Clot; Claudine Wack; Liji Shen; Maja J A de Jonge
Journal:  Cancer Chemother Pharmacol       Date:  2016-10-27       Impact factor: 3.333

5.  Glomerular hyperfiltration and β-2 microglobulin as biomarkers of incipient renal dysfunction in cancer survivors.

Authors:  Fernanda R Tibúrcio; Karla E de S Rodrigues; André R Belisário; Ana Cristina Simões-E-Silva
Journal:  Future Sci OA       Date:  2018-08-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.